Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs
of distant metastases will be treated with short-term immunotherapy + COX2-inhibitors. This
treatment will be given during the window period until surgical resection of the tumor. The
duration of treatment will be approximately 6 weeks.